Literature DB >> 18650147

An introduction to molecular targeted therapy of cancer.

H Allgayer1, S Fulda.   

Abstract

The rapidly advancing elucidation of molecular targets in human cancers during the last decade has provided an excellent basis for the development of novel therapeutics. A huge variety of potential target structures have been identified, many of which are already being exploited for therapeutic purposes. This review introduces the reader into the concept of molecular targeted therapies, and provides some prototypic examples.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650147     DOI: 10.2478/v10039-008-0025-9

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  10 in total

1.  Disrupting the networks of cancer.

Authors:  Daniel F Camacho; Kenneth J Pienta
Journal:  Clin Cancer Res       Date:  2012-03-22       Impact factor: 12.531

2.  Kinase expression and chromosomal rearrangements in papillary thyroid cancer tissues: investigations at the molecular and microscopic levels.

Authors:  H-U G Weier; J Kwan; C-M Lu; Y Ito; M Wang; A Baumgartner; S W Hayward; J F Weier; H F Zitzelsberger
Journal:  J Physiol Pharmacol       Date:  2009-10       Impact factor: 3.011

3.  Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments.

Authors:  Kenneth J Pienta; Natalie McGregor; Robert Axelrod; David E Axelrod
Journal:  Transl Oncol       Date:  2008-12       Impact factor: 4.243

4.  Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology.

Authors:  Simone Mocellin; Jeff Shrager; Richard Scolyer; Sandro Pasquali; Daunia Verdi; Francesco M Marincola; Marta Briarava; Randy Gobbel; Carlo Rossi; Donato Nitti
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

5.  Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.

Authors:  Yuying Qi; Tinghui Hu; Kai Li; Renqing Ye; Zuodong Ye
Journal:  J Breast Cancer       Date:  2015-09-24       Impact factor: 3.588

6.  ErbB4 as a potential molecular target in the treatment of esophageal squamous cell cancers.

Authors:  Ke Zhao; Bao-Jun Chen; Zhi-Guo Chen
Journal:  ScientificWorldJournal       Date:  2014-11-04

7.  Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.

Authors:  Zhiyu Wang; Neng Wang; Jianping Chen; Jiangang Shen
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-12       Impact factor: 2.629

8.  miR-302b is a potential molecular marker of esophageal squamous cell carcinoma and functions as a tumor suppressor by targeting ErbB4.

Authors:  Mingxin Zhang; Qi Yang; Lingmin Zhang; Suna Zhou; Wenguang Ye; Qinglin Yao; Zongfang Li; Cheng Huang; Qinsheng Wen; Jingjie Wang
Journal:  J Exp Clin Cancer Res       Date:  2014-01-19

9.  Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.

Authors:  Lin L Liu; Fei Li; William Pao; Franziska Michor
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

10.  Downregulation of ubiquitin-specific peptidase 39 suppresses the proliferation and induces the apoptosis of human colorectal cancer cells.

Authors:  Zhiyuan Xing; Fengbo Sun; Wang He; Zhiwei Wang; Xiuqi Song; Fengjuan Zhang
Journal:  Oncol Lett       Date:  2018-02-15       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.